Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study
Núria Guillén(Hospital Clínic de Barcelona), Albert Lladó(Hospital Clínic de Barcelona), Alberto Lleó(Hospital de Sant Pau), Aida Fernández‐Lebrero(Hospital Del Mar), José Contador(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Mircea Balasa(The Royal Melbourne Hospital), Gerard Piñol‐Ripoll(Hospital Clínico Universitario Lozano Blesa), Raquel Sánchez‐Valle(Biomedical Research Networking Center on Neurodegenerative Diseases), Maríateresa Buongiorno(University Hospital Mútua de Terrassa), Anna Carnes(Hospital Universitari de Santa Maria), Dolores Vilas(Centre Hospitalier Universitaire de Lille), Albert Puig‐Pijoan(Universitat Autònoma de Barcelona), Daniel Alcolea(Hospital de Sant Pau), Ignacio Álvarez(Mútua Terrassa), Natalia Culell(University Hospital Mútua de Terrassa), Juan Fortea(Hospital de Sant Pau)
Cited by 14
Related Papers
New insights into the genetic etiology of Alzheimer’s disease and related dementias
|Nature Genetics|2022|2.5k
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions
|Nature Genetics|2010|608
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
|Alzheimer s & Dementia|2011|412